SOCS-based strategies to impair pathological JAK/STAT activity were already reported for the treatment of cardiovascular diseases confirming the anti-inflammatory and atheroprotective properties of the SOCS1/SOCS3 gene delivery in experimental atherosclerosis models [25,26]. This evidence concerns the gene SOCS1 and atherosclerosis.